ATRA + ATO salvage for R/R APL post front-line

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ATRA` `DRUG-ATO`

ID	`REG-ATRA-ATO-APL-SALVAGE`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-APL-RELAPSE-LENGFELDER-2017` `SRC-ELN-APL-2019` `SRC-NCCN-AML-2025`

Notes

Salvage ATRA + ATO for R/R APL post front-line (especially post-ATRA-chemo or post-AIDA where ATO not used in 1L). For patients relapsing AFTER 1L ATRA + ATO, regimen often combines ATRA + ATO + gemtuzumab. AutoSCT consolidation for molecularly-CR responders extends 5-y OS to ~80%. STUB — pending Co-Lead sign-off.

Used By

Indication

IND-APL-SALVAGE-ATRA-ATO - IND-APL-SALVAGE-ATRA-ATO